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Kidney International (2017) 91, 539–551T he 2 prototypical complement-mediated kidney dis-eases are atypical hemolytic uremic syndrome (aHUS)and C3 glomerulopathy (C3G).
Atypical hemolytic uremic syndrome is an ultra-rare dis-
ease characterized by acute kidney injury, thrombocytopenia,
and microangiopathic hemolytic anemia that occurs with a
reported incidence of approximately 0.5 per million per year.
Other diseases that can present with a similar phenotype
include Shiga toxin-producing E. coli-associated hemolytic
uremic syndrome (STEC-HUS), thrombotic thrombocyto-
penic purpura, and other multisystem disorders. Criteria have
been established to facilitate the diagnosis of aHUS. At least
50% of patients with aHUS have an underlying inherited and/
or acquired complement abnormality, which leads to dysre-
gulated activity of the alternative pathway at the endothelial
cell surface. There are, however, noncomplement inherited
abnormalities such as mutations in DGKE, which can result
in an aHUS phenotype. Until recently, the prognosis for
aHUS was poor, with the majority of patients developing end-
stage renal disease within 2 years of presentation. However,
with the introduction of eculizumab, a humanized mono-
clonal antibody against C5, it is now possible to control the
renal disease and prevent development of end-stage renal
disease.
C3G is also ultra-rare (incidence approximately 1 per
million per year) and deﬁnes a group of incurable kidney
diseases driven by uncontrolled activation of the complement
cascade that leads to C3 deposition within the glomerulus.
Most frequently, dysregulation occurs at the level of the
C3 convertase of the alternative pathway in the ﬂuid phase
and is driven by genetic and/or acquired defects. Broad539
meet ing repor t THJ Goodship et al.: aHUS and C3 glomerulopathy: a KDIGO conference reportinterindividual variability gives rise to 2 major subtypes of
disease, dense deposit disease (DDD) and C3 glomerulone-
phritis (C3GN), that are resolved by characteristic ﬁndings on
renal biopsy.
The objective of this Kidney Disease: Improving Global
Outcomes (KDIGO) conference was to gather a global panel
of multidisciplinary clinical and scientiﬁc expertise to identify
key issues relevant to the optimal management of these 2
diseases and to propose a research agenda to resolve
outstanding controversial issues.RENAL PATHOLOGY
aHUS
Atypical hemolytic uremic syndrome is a “thrombotic”
microangiopathy (TMA), the pathological features of which
represent tissue responses to endothelial injury. In some
biopsies, overt thrombosis as evidenced by intraluminal ﬁbrin
or ﬁbrin-platelet plugging is not seen. Nonthrombotic fea-
tures include endothelial swelling and denudation, mesan-
giolysis, double contours of the glomerular basement
membrane, and subendothelial accumulation of electron-
lucent, ﬂocculent material. In arteries and arterioles, intra-
mural ﬁbrin, myxoid intimal thickening, and concentric
myointimal proliferation (onion-skinning) may occur. It is
illogical to describe cases with these features and clear absence
of thrombosis as thrombotic microangiopathy. We therefore
suggest referring to the process as microangiopathy, with
further speciﬁcation of whether thrombosis is present
(Table 1).
Areas of controversy and gaps in knowledge. C5b-9 stain-
ing can be seen in microangiopathy attributed to complement
abnormalities, drug toxicity, and after hematopoietic stem cellTable 1 | Morphological features in microangiopathy
Active lesions Chronic lesions
Glomeruli
 Thrombi
 Endothelial swelling
or denudation
 Fragmented red
blood cells
 Subendothelial ﬂocculent
material by EM
 Mesangiolysis
 Microaneurysms
Glomeruli
 Double contours of peripheral
capillary walls by LM, with variable
mesangial interposition
 New subendothelial basement
membrane by EM
 Widening of the subendothelial
zone by EM
Arterioles
 Thrombi
 Endothelial swelling
or denudation
 Intramural ﬁbrin
 Fragmented red blood cells
 Intimal swelling
 Myocyte necrosis
Arterioles
 Hyaline deposits
Arteries
 Thrombi
 Myxoid intimal swelling
 Intramural ﬁbrin
 Fragmented red blood cells
Arteries
 Fibrous intimal thickening with
concentric lamination (onion skin)
EM, electron microscopy; LM, light microscopy.
540transplantation.1 However, its presence is not reliable and we
do not know whether this variability reﬂects technical or
biological differences (Table 1).
In general, it is not possible to determine etiology from
morphology. Because morphologic features do not allow
identiﬁcation of etiology, it is important for the pathologist to
provide a differential diagnosis, especially in patients with
severe hypertension, where attributing changes to hyperten-
sion alone may lead to failure to identify other speciﬁc causes
such as complement dysfunction.
C3G
C3G deﬁnes a disease spectrum caused by abnormal control
of complement activation, deposition, or degradation that
results in predominant glomerular C3 fragment deposition
associated with characteristic deposits as seen by electron
microscopy (EM).2 Based on EM appearance, C3G may be
subclassiﬁed as DDD (dense osmiophilic intramembranous
deposits) or C3GN (light dense, amorphous mesangial, par-
amesangial, subendothelial, and subepithelial deposits)
(Table 2).
A renal biopsy is required to diagnose C3G. The pattern
seen on light microscopy can be very diverse, and a diagnosis
of C3G can only be made on immunoﬂuorescence (IF). The
criterion on IF with the best balance of sensitivity and spec-
iﬁcity is the presence of dominant C3 staining, with the
intensity of C3 staining at least 2 orders of magnitude greater
than any other immunoreactant (i.e., IgG, IgM, IgA, and
C1q).3 This criterion captures about 90% of DDD cases, but
possibly fewer C3GN cases.3 In the remaining cases, the initial
kidney biopsy may not show C3-dominant glomerulone-
phritis (GN), but subsequent biopsies may, reﬂecting an
evolution in disease over time and suggesting that in cases
with an atypical clinical course, repeat biopsies may beTable 2 | Morphological features of C3G
Light microscopy
Active lesions
 Mesangial expansion with or without hypercellularity
 Endocapillary hypercellularity including monocytes and/or
neutrophils
 Capillary wall thickening with double contours (the combination of
capillary wall thickening and mesangial increase is referred to as a
membranoproliferative pattern)
 Necrosis
 Cellular/ﬁbrocellular crescents
Chronic lesions
 Segmental or global glomerulosclerosis
 Fibrous crescents
Immunoﬂuorescence microscopy
 Typically dominant C3 staining
Electron microscopy
 DDD: Dense osmiophilic mesangial and intramembranous electron
dense deposits
 C3GN: Amorphous mesangial with or without capillary wall deposits
including subendothelial, intramembranous and subepithelial
electron dense deposits
 Subepithelial “humps” may be seen in both DDD and C3GN
C3G, C3 glomerulopathy; DDD, dense deposit disease; C3GN, C3 glomerulonephritis.
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C3G often presents in the context of an acute infection, and
C3 dominance can be seen in self-limiting postinfectious
glomerulonephritis. There are no morphological features in
acute exudative GN that predict resolution or progression.
Humps are no longer considered pathognomonic of post-
infectious glomerulonephritis, as they are frequently found in
C3G. Cases of acute exudative GN with double contours of
the glomerular basement membrane should heighten suspi-
cion for C3GN. EM should be conducted in all cases to
unequivocally distinguish DDD and C3GN, as this distinction
is clinically important. In addition, in light of recent
descriptions of GN with masked monotypic Ig deposits,4,5
staining for IgG and light chains on pronase-digested
parafﬁn sections should be considered for all cases of C3GN
on standard IF, especially in adults.
Areas of controversy and gaps in knowledge. There is evi-
dence that staining for C4d can distinguish C3G from
immune complex-mediated GN, though its role is not
established.5–7 Further studies on both frozen and parafﬁn
sections are required.
There are numerous knowledge gaps. Broadly, correlations
between renal biopsy appearances, etiology, and clinical
outcome including response to therapy are ill deﬁned. IF
staining is subjective and semiquantitative, and reliability and
reproducibility have not been studied. While the EM
appearance of DDD is well-deﬁned and is used as a standard
against which to assess the role of IF,3 it is not clear whether
EM appearances in C3GN are characteristic and can conﬁrm
the diagnosis if IF is equivocal. The signiﬁcance of some EM
ﬁndings, such as the hump-like subepithelial deposits, is
uncertain, and in some cases, distinguishing DDD and C3GN
by EM is difﬁcult. While it is possible to objectively assess the
density of deposits on EM, the value of this approach requires
further study.
It is possible to identify different C3 breakdown products
in glomeruli by IF8 or mass spectrometry after laser capture
microdissection.9,10 This methodology can also be used to
detect other complement components (i.e., factor H-related
proteins, C5–C9). It is not known whether some of these
complement components in speciﬁc tissue compartments
(e.g., C5b-9) might identify a subset of patients likely to
beneﬁt from a speciﬁc type of therapy (e.g., anti-C5 therapy).
An increased understanding of the signiﬁcance of different
complement components would be facilitated by detailed IF
studies using well-characterized antibodies.
CLINICAL PHENOTYPE AND ASSESSMENT
aHUS
The term aHUS has been used historically to deﬁne any HUS
not caused by STEC-HUS. Current classiﬁcations reﬂect an
increased understanding of disease mechanisms including the
impact of genetic background and etiologic triggers.11 As a
result, some clinicians now use the term “primary aHUS”
when an underlying abnormality of the alternative pathway of
complement is strongly suspected and other causes ofKidney International (2017) 91, 539–551secondary aHUS have been excluded (Figure 1). However,
even in some of these patients, a complement abnormality
will not be identiﬁed. In many patients with an underlying
complement risk factor, a trigger is required for aHUS to
manifest.12 Triggers include autoimmune conditions, trans-
plants, pregnancy, infections, drugs, and metabolic condi-
tions.13 It may be difﬁcult to show unequivocally that a trigger
unmasks latent complement defects. Additional work is
required to deﬁne the impact of complement risk factors in
these subgroups.
Acute versus chronic disease? In general, we do not
understand the time course of a clinical episode of aHUS and
whether disease activity persists. However, many patients
appear to be at life-long risk for the recurrent acute presen-
tation of aHUS. Disease penetrance for an acute episode of
aHUS is age-related, and by age 70 may be as high as 64%,14
an observation that supports the existence of additional dis-
ease modiﬁers. A small percentage (3%–5%) of patients carry
more than 1 pathogenic genetic variant, supporting a rela-
tionship between mutation burden and penetrance.15 Pre-
sentation in later life is consistent with the need for an
environmental trigger. Discordance between the pathological
and clinical manifestations of the disease is sometimes seen.
For instance, a thrombotic microangiopathy can sometimes
be present on renal biopsy in the absence of
thrombocytopenia.
The introduction of eculizumab has changed the natural
history of aHUS. Prior to eculizumab, most patients with
aHUS progressed to end-stage renal disease, at which time
the TMA process usually ceased.16 With complement
inhibitory therapy, glomerular perfusion and function are
maintained. How the renal endothelium is altered and
interacts with the complement system following withdrawal
of complement inhibitors is unclear and may be informed
by clinical trials.
C3G
In contrast to the acute presentation of aHUS, in the majority
of patients with C3G, the disease follows a chronic, indolent
course with persistent alternative pathway activation resulting
in a 10-year renal survival of approximately 50%.17 However,
cases of C3G presenting as a rapidly progressive GN are well
recognized.18–20
Extrarenal manifestations of aHUS and C3G
Extrarenal manifestations are reported in up to 20% of
patients with aHUS (Supplementary Table S1). It is unclear
whether these manifestations are a direct consequence of
complement activation, TMA, or other factors such as severe
hypertension and uremia. Interestingly, despite sharing many
of the same rare genetic variants in CFH21 and CFI22
described in age-related macular degeneration, drusen for-
mation is not commonly reported in aHUS.23
In C3G (DDD and C3GN), acquired partial lipodys-
trophy24 and retinal drusen25,26 are reported and appear to be
direct consequences of complement activation. Acquired541
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Figure 1 | TMA diagnostic ﬂow chart. Following the diagnosis of a TMA, clinical and laboratory evaluation is required to establish the etiology.
ADAMTS13 activity is urgently required to exclude TTP prior to treatment with eculizumab in adults but is not a prerequisite in children.
Investigation for STEC-HUS should be undertaken in all individuals with suspected aHUS. In all pediatric aHUS, plasma and urinary evaluation for
cblC deﬁciency is mandatory. All individuals with suspected primary aHUS should have a complete evaluation for complement-mediated aHUS.
Individuals with pregnancy-associated aHUS and de novo transplantation associated aHUS should also have a full complement evaluation due
to the high prevalence of rare genetic variants described in these subgroups. In other secondary cases of aHUS, insufﬁcient evidence exists to
recommend a full genetic evaluation, although it is noted that rare genetic variants have been described in many of these cases. Rarely, in
severe cases of STEC-HUS resulting in ESRD, rare genetic variants have been described following HUS recurrence in a subsequent renal
transplant. In cases where the role of complement is as yet unclear, the clinician should decide on the evaluation based on the clinical
consequences of positive result (e.g., listing for renal transplantation as demonstrated by the dotted line). Factor H autoantibodies have been
reported in non–small cell lung cancer, although a causative association with malignancy associated aHUS has yet to be made.107 1ary, primary;
Ab, antibody; ACA, anticentromere antibody; aHUS, atypical hemolytic uremic syndrome; ANA antinuclear antibody; anti-Scl-70, anti-topo-
isomerase I antibody; BMT, bone marrow transplant; CMV, cytomegalovirus; DGKE, diacylglycerol kinase ε; EBV, Epstein-Barr virus; ESRD, end-
stage renal disease; FACS, ﬂow cytometry; Hb, hemoglobin; Hep, hepatitis; HUS, hemolytic uremic syndrome; LDH, lactate dehydrogenase;
MAHA, microangiopathic hemolytic anemia; MLPA, multiplex ligation-dependent probe ampliﬁcation; PCR, polymerase chain reaction; Plts,
platelets; STEC-HUS, Shiga toxin E. coli HUS; Stx, Shiga toxin; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura.
meet ing repor t THJ Goodship et al.: aHUS and C3 glomerulopathy: a KDIGO conference reportpartial lipodystrophy is most commonly seen in individuals
with C3 nephritic factors. Factor D, required for formation of
the C3 convertase, is highly expressed in adipocytes, which
undergo C3 nephritic factor–induced complement-
dependent lysis.27 Drusen, the accumulation of lipids and
complement-rich proteins between Bruch’s membrane and
the retinal pigment epithelium, are commonly seen in age-
related macular degeneration but occur at an earlier age in
C3G.28
Laboratory investigations
Once routine biochemical and hematological analysis has
demonstrated a TMA, investigations should focus on deter-
mining the underlying etiology and excluding other diagnoses
(Supplementary Table S2, Figure 1). The most urgent
requirement is to measure ADAMTS13 activity to diagnose or
exclude thrombotic thrombocytopenic purpura. Because the
incidence of thrombotic thrombocytopenic purpura is much
lower in children than in adults, expert opinion recommends
that in children, treatment with eculizumab should not be
delayed while ADAMTS13 activity is being determined;542however, signs of nonresponse should be carefully monitored.
By contrast, in adults, measuring ADAMTS13 activity is
recommended prior to eculizumab initiation. Investigation
for STEC-HUS should be routine in all patients with pre-
sumed aHUS, as approximately 5% of STEC-HUS cases have
no prodromal diarrhea, whereas 30% of complement-
mediated aHUS cases have concurrent diarrhea or gastroen-
teritis (Figure 1).29Complement investigations of aHUS and C3G
Serum or plasma levels of complement proteins should be
measured in all patients with primary aHUS and C3G prior to
plasma therapy. C3 levels will be low in 30% to 50% of aHUS
cases and up to 75% of C3G cases.9,17 Low C3 levels are also
seen in the acute phase of STEC-HUS and pneumoccocal
aHUS.11 CD46 surface expression should be evaluated by ﬂow
cytometry for suspected aHUS. Complement functional
assays and activation markers can also be obtained. The
clinical interpretation of these tests requires further study.30
(Supplementary Table S3).Kidney International (2017) 91, 539–551
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aHUS
Studies of hundreds of patients with aHUS have provided an
excellent understanding of genetic drivers of disease and have
informed genotype–phenotype correlations that predict pro-
gression of disease, response to therapy, and the risk of
recurrence after transplantation. This level of understanding
supports an individualized approach to patient management
and treatment based on expert interpretation of genetic
proﬁles, and mandates genetic screening and molecular
diagnostics in every patient. Delays in obtaining results from
genetic or molecular diagnostic studies should not prevent a
clinical diagnosis or postpone treatment, as early anti-
complement treatment is crucial to preserve renal function
and avoid irreversible sequelae.31
C3G
Our understanding of the genetics of C3G is not yet com-
parable to that of aHUS, and more data are required to
inform genotype–phenotype correlations. This knowledge
gap can be addressed by screening large numbers of patients
with C3G, studying the effects of disease-associated variants
on function, and correlating these data with clinical outcomes
(Supplementary Table S4).32–35
There is no clear beneﬁt to performing genetic analysis in
every case of C3G, however genetic results may assist in
treatment decisions (i.e., anti-complement therapy vs.
immunosuppression) and should be undertaken in familial
cases and when there is suspicion of a genetic defect.36–40
Genetic testing
The minimum set of genes that should be screened in aHUS
and C3G includes CFH, CD46, CFI, C3, CFB, THBD, CFHR1,
CFHR5, and DGKE.41–46 Because of the frequent concurrence
of genetic risk factors in aHUS, this analysis should also
include genotyping for the risk haplotypes CFH-H3 and
MCPggaac.
47 Genetic analyses must include suitable technol-
ogies to detect copy number variation, hybrid genes, and
other complex genomic rearrangements in the CFH/CFHRs
genomic region.48–53
The identiﬁcation of a pathogenic genetic variant in a
patient with aHUS reinforces the diagnosis and establishes
with accuracy the cause of the disease, facilitating patient
management, effective treatment, and genetic counseling. In
C3G, however, present knowledge is insufﬁcient except in
cases of CFHR rearrangements leading to fusion genes (such
as CFHR5 nephropathy), FH or FI deﬁciency, or with C3
mutations.36–40,54,55
Genetic analysis is essential in living-related kidney donor
transplantation.56 The general recommendation in aHUS is
that transplantation from living-related kidney donors should
only be considered if causative genetic (or acquired) factors
are clearly identiﬁed in the recipient and the related donor is
free of these factors. In this setting, the presence in the donor
of CFH or MCP aHUS risk haplotypes is not a contraindi-
cation to donation.Kidney International (2017) 91, 539–551In C3G, we recommend that all planned recipients of a
living-related kidney be screened and if a genetic abnormality
is found, the donor should be tested to exclude that genetic
abnormality. If the donor is found to carry the same genetic
abnormality as the recipient, current evidence would suggest
that while this ﬁnding may not constitute an absolute
contraindication to donation, each case should be evaluated
on an individual basis by experts in this area, taking into
account the family history and speciﬁc genetic abnormality.
The theoretical risks that donation may trigger disease onset
must be discussed with the donor.
Genetic testing is recommended for patients in whom
discontinuation of anticomplement therapies is being
considered.
Understanding genetic variants. Genetic variants should
be classiﬁed as benign, likely benign, variant of uncertain
signiﬁcance, likely pathogenic, or pathogenic following
international guidelines.57
In aHUS, pathogenic variants speciﬁcally impair the
capacity to protect host endothelial cells and platelets from
complement damage or activation.58–67 It is clear that the
combination of different pathogenic variants and/or the
combination of pathogenic variants and common risk vari-
ants in CFH and MCP determine overall individual risk/
predisposition to aHUS.14,15,43,47,68–71 Genetic makeup also
inﬂuences disease progression, response to therapies, and
recurrence after transplantation (Supplementary
Table S5).56,72,73
C3G, in contrast, appears mechanistically more complex
than aHUS, with massive C3 activation in plasma and com-
plement dysregulation on surfaces, including the glycocalyx
overlying the glomerular endothelial pores.2,17,38,51,55,74–78 We
have limited information about genotype-phenotype corre-
lations to distinguish different C3G subtypes, inform prog-
nosis, and/or recommend treatment.
It is highly recommended that genetic results be inter-
preted by a laboratory with expertise in aHUS and C3G
(Supplementary Tables S6 and S7).
ACQUIRED DRIVERS OF DISEASE
aHUS
In aHUS, the best studied are FH autoantibodies, which are
typically associated with homozygosity for delCFHR3-
CFHR1. Positive results should be conﬁrmed in a second
sample at least 4 weeks after the initial sample. Testing should
also be performed in the prerenal transplant period. In pe-
diatric patients, FH autoantibody assays should be performed
following consensus guidelines: at diagnosis and, if positive, at
days 7, 14, and 28, monthly, and at 1 year.11 Relapses of anti-
FH–associated HUS occur in about 20% to 25% of patients.
C3G
In C3G, C3 nephritic factors, FH autoantibodies and, in older
adults, free light chains should be assayed (Supplementary
Table S8). The results of autoantibody assays require expert
interpretation, with their relevance to disease interpreted in543
meet ing repor t THJ Goodship et al.: aHUS and C3 glomerulopathy: a KDIGO conference reportthe context of the results for all other complement assays and
genetic screens.
TREATMENT STRATEGIES
aHUS
All patients with a clinical diagnosis of primary aHUS are
eligible for treatment with a complement inhibitor
(Supplementary Table S9). The dosing schedule reported in
the trials is recommended, although 2 options for altered
dosing have been considered: (i) the minimal dose required to
achieve complement blockade; and (ii) a discontinuation
dosing schedule.79 No data exist to support either option, and
both require monitoring of complement activity (Table 3).
The treatment of FH autoantibody–driven aHUS involves the
use of anticellular therapy and is guided by antibody titer
(Figure 2). Interruption of anticomplement therapy during
intercurrent illness, a time of high-risk for aHUS relapse, is
not recommended unless an infection with an encapsulated
organism is suspected or documented.
If access to eculizumab is unavailable, plasma therapy can
be used. Plasma exchange should also be considered for anti-
FH-positive aHUS and in the emergency treatment of criti-
cally ill patients with severe TMA (e.g., coma or convulsions)
and a strong presumption of TTP until evidence of residual
ADAMTS13 activity exceeds 10%.80 The use of plasma
exchange when eculizumab is available may be associatedTable 3 | Monitoring eculizumab therapy
CH50 (Total complement activity) Description
 Measures the co
 Tests the functio
50% of sheep e
 Will be low in c
 Normal range is
Recommended go
 <10% of norma
AH50 (Alternative pathway hemolytic activity) Description
 Measures the co
 Tests the functio
components to
 Will be low in c
during terminal
 Normal range is
Recommended go
 <10% of norma
Eculizumab trough Description
 May be a free o
 ELISA-based ass
IgG detection sy
 Not affected by
Recommended tr
 50–100mg/ml
Alternative assays The following ass
different labora
 Free C5
 In vitro human m
 sC5b-9 (also refe
aHUS patients in
aHUS, atypical hemolytic uremic syndrome; C3, complement component 3; C5, comp
immunosorbent assay; FB, complement factor B; FD, complement factor D; FH, comple
brane attack complex; TCC, terminal complement complex.
544with some improvement, but there is a risk that delaying the
onset of eculizumab may lead to a suboptimal therapeutic
outcome.
Treatment duration is controversial, and to date there is no
evidence to support lifelong therapy in all aHUS patients.
Discontinuation of plasma therapy or complement inhibition
is feasible at least in some patients with aHUS. The consensus
favored a minimal period of treatment to allow optimal renal
recovery without early relapse (Figure 3). Prospective studies
are crucial to assess parameters predictive of relapse and to
deﬁne how genetics, quality of renal recovery, age, presence or
absence of a triggering event, and biomarkers related to
complement activation and/or endothelial cell injury inform
this decision.
Eculizumab increases the risk of meningococcal infec-
tion.11 Patients should receive vaccination against meningo-
coccus, including type B; however, vaccination should not
delay the start of eculizumab. Antibiotic prophylaxis is
mandated during the ﬁrst 2 weeks. Controversy remains as to
whether vaccination is efﬁcacious in patients with acute
kidney injury, chronic kidney disease, and/or during immu-
nosuppression. It is unknown whether antimeningococcal
antibodies are protective in the setting of complement
blockade; therefore, it is recommended that antibiotic pro-
phylaxis be maintained for the treatment duration and up to 2
to 3 months after discontinuation.mbined activity of all of the complement pathways
nal capability of serum complement components to lyse
rythrocytes in a reaction mixture
ongenital complement deﬁciency (C1–8) or during complement blockade
assay dependent
al during therapeutic complement blockade
l
mbined activity of the alternative and terminal complement pathways
nal capability of alternate or terminal pathway complement
lyse 50% of rabbit erythrocytes in a Mg2þ-EGTA buffer
ongenital C3, FI, FB, properdin, FH, and FD deﬁciencies or
complement blockade
assay dependent
al during therapeutic complement blockade
l
r bound level
ay using C5 coated plates, patient sera, and an anti–human
stem
complement deﬁciencies
ough level during therapeutic complement blockade
ays are under investigation (or awaiting to be replicated in
tories)62 as a means to monitor therapeutic complement blockade
icrovascular endothelial cell test62
rred to as sMAC and TCC) may remain detectable in
remission and therefore is not recommended as a monitoring tool
lement component 5; EGTA, ethyleneglycol tetraacetic acid; ELISA, enzyme-linked
ment factor H; FI, complement factor I; sC5b-9, soluble C5b-9; sMAC, soluble mem-
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Clinical diagnosis 
of 
aHUS
Plasma therapyb
Simultaneous start of 
anticellular therapyc
Periodic monitoring of 
FH autoantibody 
levele
Discontinue therapy 
when antibody titer 
falls below a 
pathogenic titer for at 
least 6 monthsf
Continue plasma 
therapy indefinitelyd
Eculizumab
Simultaneous start of 
anticellular therapyc
Periodic monitoring of 
FH autoantibody 
levele
Discontinue therapy 
when antibody titer 
falls below a 
pathogenic titer for at 
least 6 monthsf
Continue eculizumab  
therapy indefinitelyd
High titer 
FH autoantibodya
Figure 2 | Treatment of complement factor H autoantibody-mediated aHUS. There are no prospective controlled studies in patients with
atypical hemolytic uremic syndrome (aHUS) due to anti–factor H protein (FH) antibodies, and thus the proposed management is based on a
pediatric consensus.11
aAbnormal titer depends on the testing laboratory.
bThe decision to use plasma therapy versus eculizumab will be based on patient age and local resource availability.
cCyclophosphamide, rituximab, or mycophenolate mofetil.
dThe decision to continue anticomplement therapy indeﬁnitely is not informed by data.
eThe interval may be monthly or quarterly and is based on local resources.
fThis recommendation is based on limited retrospective case reviews.108–110
THJ Goodship et al.: aHUS and C3 glomerulopathy: a KDIGO conference report mee t ing repor tDocumentation of increased complement activ-
ity11,31,79,81,82 in the setting of aHUS after an external trigger
suggests clinical beneﬁt of complement blockade especially in
the setting of severe sequelae.17,77,83 However, in the absence
of trial data, complement inhibition in these forms of aHUS
remains controversial.
Transplant. Kidney transplantation should be delayed
until at least 6 months after the start of dialysis because
limited renal recovery may occur several months after starting
eculizumab.82,84 The resolution of hematological TMA fea-
tures and extrarenal manifestations is a prerequisite for
transplantation. The decision to use anticomplement therapy
during transplantation should be based on recurrence risk
(Table 4).
Living-related kidney donation carries a risk for recurrence
in the recipient and a risk of de novo disease in the donor
should the donor carry an at-risk genetic variant.81 Potential
donors with evidence of abnormal alternative complement
pathway activity should be excluded. If the potential living-
related donor does not carry a pathogenic variant in aKidney International (2017) 91, 539–551complement gene and has no evidence of abnormal com-
plement activation, donation is feasible.31
Liver transplant remains an option in patients with liver-
derived complement protein abnormalities, in particular for
renal transplant recipients with uncontrolled disease activity
despite eculizumab therapy.85
C3G
A single randomized controlled trial using steroid as mono-
therapy in mesangiocapillary GN83 has been published. Given
the change in terminology and disease characterization and
the potential confounding effect on trial stratiﬁcation, the
results of this trial are of limited use in guiding current
treatment considerations for C3G. A retrospective study
supports the effectiveness of mycophenolate mofetil in a select
group.86 Outlined here is a tiered approach to treatment
based primarily on expert opinion, with limited support from
retrospective cohort studies87–103 (Table 5). In the absence of
more speciﬁc data, monitoring of anticomplement therapy
should be similar to that used in aHUS (Table 3).545
Clinical diagnosis 
of 
aHUS
Adult Child
Complete recovery of 
renal function in children 
>3 years of age
Transplant
Transplant patients, 
especially those who 
have lost previous 
allografts, are not good 
candidates for treatment 
cessation  
Minimal period of 
treatment and absence 
of extrarenal disease
If eculizumab is to be discontinued close periodic monitoring of renal function and 
hematological parameters is mandatory. There are NO data to inform the frequency of 
testing 
Figure 3 | Recommendations for cessation of treatment with complement inhibitors. There are no prospective controlled studies in
patients with atypical hemolytic uremic syndrome (aHUS) to deﬁne criteria for discontinuation of eculizumab therapy. This ﬂow diagram is
based on expert opinion.111–114 Discontinuation can be considered on a case-by-case basis in patients after at least 6 to 12 months of treatment
and at least 3 months of normalization (or stabilization in the case of residual chronic kidney disease) of kidney function. Earlier cessation
(at 3 months) may be considered in patients (especially children) with pathogenic variants in MCP if there has been rapid remission and
recovery of renal function. In patients who have undergone dialysis, eculizumab should be maintained for at least 4 to 6 months before
considering discontinuation. In this setting, the assessment of ﬁbrotic changes in the kidney using a biopsy may be helpful. In patients who
have undergone transplant, especially patients who have lost previous allografts, discontinuation is not recommended.
meet ing repor t THJ Goodship et al.: aHUS and C3 glomerulopathy: a KDIGO conference reportNo speciﬁc recommendation can be made for plasma
therapy or rituximab (an anti-CD20 antibody). The confer-
ence attendees acknowledged published reports that support
the effectiveness of plasma therapy in the setting of C3G
induced speciﬁcally by pathogenic variants in factor H;
however, this approach appears to be beneﬁcial to only a
select subgroup of patients with C3G.77
Transplant. No speciﬁc data are available to inform de-
cisions surrounding transplantation in C3G. Recommenda-
tions reﬂect expert opinion and limited case reports
(Supplementary Table S10). C3G recurs in allografts at a high
rate, leading to graft loss in approximately 50% of patients.
RESEARCH RECOMMENDATIONS
We believe a cross-disciplinary approach should be under-
taken for the recommendations listed below. This should
include combining pathology, clinical phenotyping, genetics,
and therapy prospectively using scoring systems such as the
MEST score in IgA nephropathy.104
Renal pathology
aHUS. A comparative study of biopsies from patients
with well-documented malignant hypertension and patients546with well-documented alternative complement pathway
disease is required to identify morphological and/or immu-
nohistochemical features that may distinguish between these
groups. A longitudinal study of patients with features of
chronic microangiopathy on biopsy but without a history of
acute presentation is needed to deﬁne associations with
clinical features, etiology, and outcome.
C3G. A comprehensive study is needed to deﬁne the
relationship of morphology to etiology, clinical course, and
response to therapy, which would be best achieved by a
multicenter collection of well-annotated cases, analyzed by a
group of renal pathologists in a manner similar to that used
for the Oxford classiﬁcation of IgA nephropathy.105,106 The
study should include: light microscopy with histologic
markers of activity and chronicity; IF, including routine
studies together with staining for C3 fragments and other
complement proteins; and EM, including objective assess-
ment of deposit density, quantity, and distribution.
Clinical phenotype and evaluation of aHUS and C3G
A consensus on the terminology covering TMAs and aHUS
should be sought as more information concerning their
pathogenesis becomes available.Kidney International (2017) 91, 539–551
Table 5 | Recommended treatment approach for C3Ga
All patients  Optimal blood pressure control (suggested
blood pressure below the 90% in children
and #120/80 mm Hg in adults)
B Priority agents include angiotensin converting
enzyme inhibitors and angiotensin receptor
blockers
 Optimal nutrition for both normal growth in
children and healthy weight in adults
 Lipid control
Moderate disease Description
 Urine protein over 500 mg/24 h despite
supportive therapy
or
 Moderate inﬂammation on renal biopsy
or
 Recent increase in serum creatinine suggesting
risk for progressive disease
Recommendation
 Prednisone
 Mycophenolate mofetil
Severe disease Description
 Urine protein over 2000 mg/24 h despite
immunosuppression and supportive therapy
or
 Severe inﬂammation represented by marked
endo- or extracapillary proliferation with or
without crescent formation despite
immunosuppression and supportive therapy
or
 Increased serum creatinine suggesting risk for
progressive disease at onset despite
immunosuppression and supportive therapy
Recommendation
 Methylprednisolone pulse dosing as well as
other anti-cellular immune suppressants have
had limited success in rapidly progressive disease
 Data are insufﬁcient to recommend eculizumab
as a ﬁrst-line agent for the treatment of rapidly
progressive disease
C3G, C3 glomerulopathy.
aBased on a single, small prospective trial, case reports, and expert opinion.
Table 4 | Prophylaxis against aHUS recurrence in allografts
based on a risk-assessment strategya
Recurrence risk Treatment regimen
High risk (50-100%)
 Previous early recurrence
 Pathogenic mutationa
 Gain-of-function mutation
Prophylactic eculizumabb,c
Note: Start on the day of
transplantation due to
potential for severe
recurrence and limited
recovery of function
in renal grafts compared
with native kidneys
Moderate risk
 No mutation identiﬁed
 Isolated CFI mutations
 Complement gene
mutation of unknown signiﬁcance
 Persistent low titer FH autoantibody
Prophylactic eculizumab or
plasma exchanged
Low risk (<10%)
 Isolated MCP mutations
 Persistently negative FH
autoantibodies
No prophylaxis
aHUS, atypical hemolytic uremic syndrome; CFI, complement factor I gene; FH,
complement factor H protein; MCP, membrane cofactor protein gene.
aRequires complete screening of all genes implicated in aHUS.
bProphylactic regimens are based on local center protocols; no trial data exist to
support superiority of 1 protocol over another.
cLiver transplantation can be considered for renal transplant recipients with liver-
derived complement protein abnormalities, uncontrolled disease activity despite
eculizumab therapy, or ﬁnancial considerations regarding cost of long-term eculi-
zumab therapy.
dThe decision to perform or not to perform prophylactic plasma exchange or
complement inhibition is left to the discretion of the clinician.
THJ Goodship et al.: aHUS and C3 glomerulopathy: a KDIGO conference report mee t ing repor tClinical studies are required to deﬁne how complement
biomarkers correlate with current or impending aHUS
relapse and/or renal involvement, to identify risk factors for
aHUS relapse upon cessation of anti-complement therapy, to
identify alternative anticomplement therapeutics for aHUS, to
assess the value of proximal (at the level of the alternative
pathway) anticomplement therapy in C3G, and to determine
whether complement biomarkers can inform clinical
outcome in C3G patients.
Genetic and acquired drivers of disease
Genetic testing should be undertaken in all persons with
suspected primary aHUS, although in cases of secondary
aHUS, the role of genetic testing must be clariﬁed. Exceptions
include de novo posttransplant aHUS and pregnancy-
associated aHUS, both of which require genetic testing.
In C3G, except for particular cases, present knowledge is
insufﬁcient to establish robust phenotype–genotype correla-
tions. Comprehensive genetic testing is required to ﬁll this
knowledge gap.
The impact of acquired autoantibodies such as C3
nephritic factor and FH autoantibody must be followed in
longitudinal studies to deﬁne their relevance to disease course
in the context of the results of all other complement assays
and genetic screening.Kidney International (2017) 91, 539–551In patients with aHUS and C3G in whom neither genetic
nor acquired drivers of disease are identiﬁed, concerted
efforts should be made to elucidate disease triggers.
Treatment and clinical trial strategies for aHUS and C3G
Despite remarkable advances in our understanding of the
underlying pathological mechanisms involved in C3G and
aHUS, much remains to learn about treatment. Because
eculizumab has altered the natural history of aHUS, contro-
versy has arisen in several areas of treatment. Dosing schedule
and treatment duration remain controversial and should be
rigorously studied.
The treatment of C3G has not been studied thoroughly. In
the absence of trial data, retrospective reviews, case studies, and
expert opinion inform the current approach to C3G treatment.
The development and trial of complement inhibitors as
therapeutic interventions for C3G is a high priority. For the
purposes of selecting patients for clinical trials, the conference
participants felt that only a single phenotypic parameter547
meet ing repor t THJ Goodship et al.: aHUS and C3 glomerulopathy: a KDIGO conference reportwarranted consideration: the EMdesignation as either DDD or
C3GN. While data demonstrating that EM will predict
treatment response to current therapeutic options are lacking,
limited retrospective studies suggest that there is a difference in
renal survival between the 2 groups.17
Although stratiﬁcation based on sC5b-9 appears
appealing,88 particularly when considering terminal comple-
ment blockade therapeutics, there is a paucity of data
to support the reliability of this assay as a true marker of
disease pathology. There is also insufﬁcient evidence to
support stratiﬁcation according to C5b-9 staining of renal
biopsy tissue. The conference participants believed there
was sufﬁcient evidence in other glomerular diseases to
exclude patients from C3G trials if they were stable on prior
supportive therapy or immune suppression after a 3-month
period, had rapidly progressive disease, or had more than
25% sclerosis on renal biopsy.
CONCLUSION
In this report, we document the proceedings of a KDIGO
Controversies Conference on the management of aHUS and
C3G. We have made recommendations pertinent to the
diagnosis and treatment of patients with these 2 diseases
based on current expert opinion practices. In addition, we
have identiﬁed knowledge gaps and offered suggestions for
future research. While there are knowledge gaps in both
diseases, it is clear that the evidence base for the management
of patients with C3G lags behind that of aHUS, and
addressing this disparity should be a priority. Though we
have presented these 2 diseases as distinct entities, it is clear
that there is substantial overlap not only in the pathogenesis
but also in the clinical presentation such that some patients
may show features of both. This should not be overlooked.
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